On This Day in Health: May 4, 2018
On May 4, 2018, the U.S. Food and Drug Administration approved the combination of dabrafenib and trametinib for certain patients with anaplastic thyroid cancer. The decision applied to advanced disease associated with the BRAF V600E mutation when satisfactory local treatment options were unavailable. Marketed as Tafinlar and Mekinist by Novartis, the medicines had already been used together in other cancers with related molecular features. Their new indication brought a targeted approach to a rare and particularly aggressive thyroid malignancy. The important change was not approval for thyroid cancer in general, but recognition that a specific genetic alteration could identify patients for a defined treatment.
Anaplastic thyroid cancer behaves differently from the more common forms of thyroid cancer. Its rapid growth and tendency to spread can make treatment especially difficult. A tumor's location provides one part of the diagnosis, but genetic testing can reveal another: changes in signaling pathways that help cancer cells continue growing. BRAF V600E is one such alteration. Dabrafenib inhibits BRAF activity, while trametinib blocks MEK, another component of the same signaling pathway. Using them together attempts to interrupt the pathway at two points. This biological rationale linked anaplastic thyroid cancer with selected melanomas and lung cancers already treated using the combination.
The evidence included an open-label trial involving rare cancers with the relevant BRAF mutation. In the thyroid cancer group described by the FDA, twenty-three patients could be evaluated for tumor response. Most of the reported responses were partial shrinkage rather than disappearance of all measurable disease. Evidence from the drugs' use in other molecularly selected cancers also contributed to the review. The small study reflected the difficulty of researching a rare illness, while also setting limits on what could be concluded. Tumor shrinkage provided a meaningful signal of activity; it did not mean that every eligible patient would respond or that the combination had become a cure.
Treatment also carried substantial risks. Fever, fatigue and gastrointestinal symptoms were among common adverse effects, and serious complications involving bleeding, the heart, eyes and other organs required attention. The drugs therefore needed specialist oversight rather than being viewed as a simple replacement for all existing care. May 4 is remembered for expanding a precision medicine strategy into a disease with few satisfactory options. Its broader significance lies in the combination of tissue diagnosis, molecular testing and careful interpretation of limited clinical evidence. The approval showed how medicines developed for one cancer could become relevant to another when tumors shared a biologically important target, while preserving the need to judge benefits and harms in the actual patients being treated.
The approved population had anaplastic thyroid cancer with BRAF V600E.
The combination blocked two points in a cancer-growth signaling pathway.
The FDA described response evidence from a small rare-cancer study.
Tumor response did not establish a cure or guarantee benefit for every patient.
Serious adverse effects required careful clinical monitoring.
The decision extended a molecularly selected treatment approach across cancer types.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.